24/7 Market News Snapshot 31 October, 2024 – Genprex, Inc. Common Stock (NASDAQ:GNPX)

October 31, 2024

DENVER, Colo., 31 October, 2024 (247marketnews.com) – (NASDAQ:GNPX) are discussed in this article.
Genprex, Inc. has demonstrated notable momentum in its stock performance, experiencing a significant surge in today’s trading session. Starting at $2.07, the stock climbed to $2.385, marking an increase of 18.07% from the previous close of $2.020. The current volume stands at 1.78 million shares, reflecting heightened investor interest and bullish sentiment surrounding GNPX. However, market participants are advised to keep an eye on resistance levels, as technical indicators suggest the stock may be overbought, indicating possible future corrections amidst this volatility.

In addition to its market activity, Genprex is gearing up for its participation in the forthcoming BIO Europe Conference, taking place from November 4-6, 2024. This esteemed event will facilitate both in-person and virtual engagement, allowing Genprex to connect with industry leaders, investors, and potential partners.

Senior Vice President of Intellectual Property and Licensing, Thomas Gallagher, Esq., will represent the Company in person, while President and CEO Ryan Confer, alongside Chief Medical Officer Mark Berger, MD, will participate virtually. Their engagement aims to underscore Genprex’s advancements in gene therapy, specifically its innovative therapies aimed at treating cancer and diabetes.

At the conference, Genprex plans to hold one-on-one meetings to delve deeper into its pioneering therapies, including the Oncoprex® Delivery System, which effectively targets tumor cells using a non-viral delivery method, as well as novel diabetes therapies that focus on enhancing pancreatic function. The Company’s leading candidate, Reqorsa® Gene Therapy, is currently undergoing clinical trials for non-small cell lung cancer and small cell lung cancer, with both therapies having received Fast Track Designation from the FDA.

Genprex’s presence at BIO Europe represents an important opportunity to foster collaborations and accelerate the development of treatments for patients facing significant healthcare challenges.

Related news for (GNPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.